340binformed.org

Your Free Source for 340B News and Commentary

  • About us
  • Advertise
  • Contact
  • 340B Health

Mylan EpiPen Settlement Provides for 340B Overcharging Claims


 

Print Article

August 17, 2017—The U.S. Justice Department, CMS, and EpiPen manufacturer Mylan announced today that Mylan has reached a $465 million settlement with the government to resolve claims it knowingly misclassified EpiPen as a generic drug to avoid paying Medicaid drug rebates.

Mylan said the settlement provides for “potential claims by certain hospitals and other covered entities that participate in the 340B Drug Pricing Program.” There were no further details.

CMS said “Mylan will reclassify EpiPen as a brand name drug consistent with the Medicaid statute and regulations. In addition, Mylan has agreed to use the correct reference price of the 3rd quarter of 1990 for the purpose of calculating inflationary payment rebates under the Medicaid Drug Rebate (MDR) program, saving the Medicaid program hundreds of millions of dollars. These changes will be effective retroactive to April 1, 2017.”

FOLLOW | SHARE | LIKE

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

340B Health Twitter

Twitter feed is not available at the moment.

RSS 340B Employed

  • Specialty Pharmacy Manager needed in Southwestern Missouri Health System JOB-3068922 | CompHealth July 10, 2025
  • Coordinator Pharmacy 340B Program - Longview Pharmacy - Full Time | CHRISTUS Health July 10, 2025
  • Pharmacist - 340B Coordinator - Hybrid | Cedars Sinai July 10, 2025
  • Compliance Analyst, 340B Program ( On-Site ) | WMCHealth July 10, 2025
  • Pharmacy Business Manager | Nemours July 10, 2025

Copyright © 2025 · 340B Health